2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
64
Neoplasms
7
Neoplasms, Plasma Cell
6
Recurrence
5
Hematologic Neoplasms
4
Renal Insufficiency
3
Paraproteinemias
3
Lymphoma
3
Immunoglobulin Light-chain Amyloidosis
3
Hematologic Diseases
3
Smoldering Multiple Myeloma
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms by Histologic Type
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Blood Protein Disorders
2
Purpura
1
Prostatic Neoplasms
1
Neoplasm, Residual
1
Nausea
1
Natural Killer/T-cell Lymphoma
1
Monoclonal Gammopathy of Undetermined Significance
1
Macroglossia
1
Lymphoproliferative Disorders
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphadenopathy
1
Leukemia, Plasma Cell
1
Immunoproliferative Disorders
1
Interventions
Cyclophosphamide
23
blinatumomab
18
Cytarabine
16
fludarabine
13
Azacitidine
12
venetoclax
10
fludarabine phosphate
10
Rituximab
8
Blood Specimen Collection
8
Methotrexate
7
Lenalidomide
7
Dexamethasone
7
Daunorubicin
7
Mercaptopurine
6
Vincristine
5
daratumumab
4
Whole-Body Irradiation
4
Melphalan
4
Idarubicin
4
Etoposide
4
Drug Therapy
4
Busulfan
4
pembrolizumab
3
obinutuzumab
3
Radiotherapy
3
Neoadjuvant Therapy
3
Maintenance
3
Liquid Biopsy
3
Immunotherapy, Adoptive
3
Imatinib Mesylate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
isatuximab
×
Clear all
NCT05690984
2026-03-16
EMAT
Medical College of Wisconsin
Phase 2
Active not recruiting
30 enrolled